Navigation Links
European Research Council supports search for regulators of tissue damage
Date:1/27/2012

There is more to fighting infection than just clearing the body of pathogens. As important as resisting infection, is limiting damage to the host's tissue caused, very frequently, by toxins produced by pathogens or by components of the host immune response that clears those pathogens. Indeed, it is the damage inflicted to different tissues and organs that, if uncontrolled, can lead to the lethal outcome of some infectious diseases.

The in-built capacity that an infected individual has to limit the extent of tissue damage caused by different pathogens, a phenomenon known as 'tolerance to infection', has fascinated Miguel Soares, a group Leader at the Instituto Gulbenkian de Cincia (IGC) in Portugal, for several years. Now, the European Research Council (ERC) has awarded his team an Advanced Grant of just over 2,2 million Euros, to investigate the mechanisms involved in this protective response. This line of research should identify and pave the way to the development of new therapeutic interventions, to quell the clinical outcome of various diseases.

Miguel Soares and his research team have already identified a restricted number of mechanisms, regulated by specific genetic programmes that control tissue damage in response to different types of infection. They have shown that these protective mechanisms are active for example against severe forms of malaria and severe sepsis. The researchers believe, however, that other protective mechanisms controlled by groups of so-called "protective genetic programmes" can act in a similar manner in the context of different diseases. Their aim is to identify these protective mechanisms, and describe how the genetic programs act, so that these may be targeted to treat a whole range of infectious diseases.

Says Miguel Soares, "Infectious diseases such as malaria and severe sepsis remain medical challenges today, acting as major killers across the globe. Our data suggest that one of the reasons for this is that current available therapy is directed almost exclusively at clearing the pathogens causing these diseases, with no regard to controlling tissue damage. Our research directly addresses the hypothesis that controlling tissue damage should also be considered as a crucial arm in fighting infectious diseases. We expect to identify therapeutic targets to obtain that effect".

The ERC Advanced Grants are awarded to "exceptional", established researchers, to "pursue ground-breaking, high-risk projects that open new directions in their respective research fields or other domains", on the basis of scientific excellence alone, across three research domains. In the 2011 competition, 294 of 2284 applications are to be funded (corresponding to a success rate of 12%).

Of the 20 applications from scientists working in Portugal, two were selected: Miguel Soares' team, in life sciences, and another in social sciences and humanities. This is only the second ERC Advanced Grant to be awarded to a senior life scientist working in Portugal, and both have gone to IGC researchers. Furthermore, of the 18 ERC grants awarded to scientists working in Portugal, across all research domains and all levels of funding (staring and advanced), seven have been awarded to IGC scientists.


'/>"/>

Contact: Ana Godinho
agodinho@igc.gulbenkian.pt
351-214-407-959
Instituto Gulbenkian de Ciencia
Source:Eurekalert  

Related biology news :

1. European Geosciences Union General Assembly, April 22-27, 2012, Vienna, Austria
2. Cell Therapeutics, Inc. Expects That the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvriâ„¢ in Mid-February
3. European mountain vegetation shows effects of warmer climate
4. DTU is participating in a European network on measurement of greenhouse gases
5. Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux
6. UK invests £75 million in European research infrastructure to support knowledge-based economy
7. EMBO awards Installation Grants to 7 European scientists
8. How does a plant survive with few mates or pollinators? A European herb has figured out its own way
9. New European project launched to address shortcomings in climate data
10. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
11. Genomatix to partner in $41 million European epigenomics consortium
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
European Research Council supports search for regulators of tissue damage
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/16/2017)... SAN FRANCISCO , Feb. 16, 2017 /PRNewswire/ ... research, today announced that it has received Laboratory ... The CAP Accreditation is presented to laboratories that ... and who demonstrate scientifically rigorous processes. ... of excellence in laboratory practices. We,re honored to ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... TARRYTOWN, N.Y. , March 22, 2017 Regeneron ... among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK ... in the U.K. Biobank resource. The initiative will enable researchers ... of new medicines for a wide range of serious and ... ...
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
Breaking Biology Technology: